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Chewing the fat on veterinary toxicology: the path to discovery 
 
Last year approximately 15% of the published articles in this Journal related to the 
field of toxicology. It is not surprising that toxicology should feature so prominently 
in a journal devoted in Emergency Medicine. Many toxins cause severe injury and 
even death if left untreated and most require immediate action. In cases of possible 
or suspected toxin exposure, conventional therapy dictates that efforts should be 
made to limit absorption of substances that were ingested by inducing emesis and 
following this by the administration of activated charcoal. In regards to activated 
charcoal administration, there are recommendations that the addition of cathartics 
to activated charcoal, such as sorbitol, or repeated dosing are indicated in case that 
the toxins undergo enterohepatic circulation. These principles have remained 
unchanged and unchallenged for many years. The problem is then how do we know 
if there are better ways to manage intoxicated patients? Are there additional 
treatments that should become part of standard protocols? Are there interventions 
(eg, repeat dosing) that have little impact of course of disease? Many of these 
questions are difficult to address, especially when these involve clinical patients.  
One approach is to use experimental models whereby animals are subjected to 
known doses of toxicants, and interventions are evaluated in their ability to reduce 
some measure – either the presence of the toxin or the clinical sign associated with 
intoxication. Such an approach is described in this issue by Koenigshof et al, 
whereby different methods of activated charcoal use are tested against a placebo 
treatment group.1 The authors sought to evaluate whether the addition of sorbitol to 
activated charcoal or repeat administration of activated charcoal indeed improved 
clearance of a toxin (in this case carprofen) known to cause severe injury in dogs. It 
is worthwhile to note that in this experiment,1 blood concentration of the toxin was 
the endpoint and not any measure of the clinical manifestation of intoxication with 
carprofen. The key findings of this study1 should lead to some rethinking (and likely 
further investigation) to what has become standard recommendations; the use of 
repeat dosing of activated charcoal when the toxin is believed to undergoes 
enterohepatic recirculation. While there were clear benefits associated with the 
addition of sorbitol to activated charcoal and repeat dosing when compared to 
placebo, there was limited improvement noted in the treatment groups, which 
raises the question whether much is gained by the addition of sorbitol or repeating 
administration of activated charcoal, at least in the context of the experimental 
design.1 
Although there are a number of advantages to carrying out experimental 
toxicological studies, it could take a number of years before clinical applications can 
be tested and shown to improve patient care. A case in point was that it took 8 years 
for the first successful clinical application of intravenous lipid therapy as a 
treatment for bupivacaine toxicity2 to be reported following the seminal publication 
by Weinberg et al3 on an experimental rodent model of lipid infusion therapy in 
1998. Since then an entire new field of toxicology revolving around intravenous 
lipid therapy has been spawned, and the literature includes various veterinary 
reports that have been recently reviewed.4 There are now over 100 hundred 
publications related to intravenous lipid therapy including experimental animal 
studies, clinical case studies and review articles. Given that intravenous lipid 
therapy is becoming more widely practiced based as evidenced by various case 
studies and recommendations by various veterinary poison centers, one could 
question why there is a need to publish further examples where such therapy may 
have a role in managing patients with toxicities. The simple answer is that there is 
still much to learn and understand about intravenous lipid therapy and although 
studies (be they experimental or case reports) have their flaws, they can still offer 
valuable information. Despite the large number of studies on the subject, the exact 
mechanism by which intravenous lipid therapy “rescues” patients remains 
incompletely understood.5 Theories have been put forth and continue to evolve as 
more data is generated. A recent shift in our understanding is that it is perhaps 
more appropriate to describe the main mechanism as a “lipid shuttle” rather than a 
“lipid sink” as the substance bound to lipid is simply surrounded and transported to 
a different organ (eg, liver, kidney, muscle) for detoxification or elimination.5 An 
important aspect that must be recognized is that the body must be able to cope with 
the toxic substance somehow, as intravenous lipid can only compartmentalize, 
transport and delay the interaction between the toxic substance and its target 
tissue. The lipids themselves cannot degrade the toxic substance.  
In this issue of the Journal there are number of new studies that offer some 
additional insights relating to intravenous lipid therapy in the context of toxicology. 
In contrast to the study mentioned previously by Koenigshof et al,1 where ingestion 
of toxic doses of non-steroidal anti-inflammatory drugs are treated with different 
activated charcoal therapies, the case series by Herring et al6 describe the use of 
intravenous lipid therapy as an adjunct treatment to standard approach of inducing 
emesis, repeat administration of activated charcoal with and without sorbitol in 
cases of ingestion of toxins.6 The maximal possible dose ingested in these cases 
(range 61-207 mg/kg of naproxen) would have certainly led to severe toxicities, yet 
these patients did not experience any major sequelae.6 It is perhaps worthy of 
mention that intravenous lipid therapy was used before the onset of any clinical 
signs, and so in this study, intravenous lipid therapy was used to mitigate the 
development of toxic injury. However, the lack of a control (eg, standard therapy 
without intravenous lipid therapy) prevents the true assessment whether lipids 
offered additional protection in these cases. Nevertheless, the authors did document 
a dramatic decrease in plasma concentrations of naproxen following intravenous 
lipid therapy in these cases that cannot be attributed to any other intervention as 
gastrointestinal decontamination does not alter plasma concentration of substances. 
This case series was highly suggestive that lipid therapy prevented the development 
of the expected morbidity given the doses of naproxen ingested, and that lipid 
therapy was associated with rapid reduction in plasma concentrations of naproxen 
given its predicted plasma half-life.  
The administration of intravenous lipid therapy to prevent or mitigate the 
development of toxic signs as opposed to treat following the development of clinical 
signs is debatable as all interventions carry some risks. Offering some potential 
insights or perhaps an opportunity to refine our questions, the case study by 
Jourdan et al7 does allows us to explore this point, albeit with various limitations. 
Although one would probably not design a prospective study in this manner, the 
authors faced a unique clinical situation whereby 20 cats from a cattery were 
simultaneously presented following accidental 20-fold overdose of ivermectin. At 
presentation, no cat showed signs of intoxication. Each cat was treated with at least 
one infusion of intravenous lipid emulsion, however, 4 cats received additional 
treatment with intravenous lipids in the form of constant rate infusion for 30 
minutes. In the event a cat developed clinical signs following this initial approach, 
additional boluses and infusions of intravenous lipid emulsions were planned. The 
interesting observations were that asymptomatic cats that were treated with a 
bolus followed by a 30-minute infusion (n=4) appeared to be ‘protected’ from the 
toxic effects of the ivermectin overdose, as compared to 6 of 16 cats treated with an 
initial single bolus of intravenous lipid that went on the development clinical signs 
and require further treatment. Additional observations included that body condition 
scores (a measure of body fat) may influence the risk for developing clinical signs 
associated with ivermectin toxicity and that an initial bolus followed by a 30-minute 
infusion of intravenous lipid may reduce the risk of toxicity.7 Although these 
findings need to be confirmed with carefully designed prospective controlled 
studies, this clinical report makes a compelling case that this protocol is worth 
considering.  
In regards to investigating the effects and potential benefits of intravenous lipid 
therapy in cats with a similar toxin, permethrin, Peacock et8 al report the largest 
randomized controlled trial in cats. In this trial, investigators chose to evaluate the 
impact of intravenous lipid therapy on course of clinical signs associated with 
permethrin toxicity. For this, investigators needed to develop a grading scheme to 
stratify patients into various stages of the disease based on semi-objective criteria 
and then reassess cats following an infusion of intravenous lipid emulsion or a 
placebo. The main findings of this study were that an intravenous lipid infusion 
appeared to reduce the time required to recover from intoxication.8 Entry criteria 
required cats to display advanced signs of intoxication before treatment and so this 
study excluded cases that were asymptomatic at presentation or presented at the 
early stages of  intoxication.8 Although the study findings does support the use of 
intravenous lipid therapy in cases of permethrin toxicity in cats, further studies are 
required to evaluate optimal dosing and treatment protocols.  
It would be fair to say that recent interest and application of intravenous lipid 
therapy in veterinary toxicology has been very exciting, although we still have much 
to learn. The fact that we have reached the point where we now have prospective, 
randomized, placebo-controlled clinical trials in relation to intravenous lipid 
therapy does not necessarily mean that we cannot learn from individual case 
reports and retrospective studies. In order to formulate the right questions, design 
and carry out prospective studies, we do rely of having ample descriptive data about 
the clinical presentation, the course of progression and outcome of animals affected 
by various toxins.  So contributions such as those made by Hickey et al,9 DuHadway 
et al10 and Katzenbach et al11 each provide needed data to improve our 
understanding of the toxicities presented and the clinical course of intoxications. It 
is with these types of information that we can one day evaluate efficacy of novel 
treatment protocols. If there is one thing we have learned from our experience with 
intravenous lipid therapy is that we don’t know where the next breakthrough will 
emerge and that progress does occur if you ask the right questions and pursue 
various lines of enquiry.   
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